Skip to main content
. 2018 Aug 23;7:30–39. doi: 10.1016/j.isci.2018.08.016

Figure 2.

Figure 2

Expression of Pluripotency Markers of Human iPSCs Maintained in StemFlex or TeSR-E8

(A–L) Representative immunostainings for TRA-1-60 and OCT-4. Images of human iPSCs cultivated in StemFlex (TOB0474) or TeSR-E8 (MBE2901) at day 8 post-passaging (p8), for TRA-1-60 (A and G) or OCT-4 (D and J), with DAPI nuclei counterstain (B, E, H, and K) and merged images (C, F, I, and L). Images are representative of all cell lines. Scale bars: 100 μM.

(M and N) Quantification of pluripotency markers. Scatterplot with bar of human iPSCs cultivated in (M) StemFlex (TOB0224; TOB0431; FSA0006; IST2168; IST2607; TOB0474; MBE2906; FSA0001; MBE1006) or (N) TeSR-E8 (TOB0421; FSA0005; TOB0199; FSA0002; MBE2909; TOB0435; MBE2900; TOB0412) at day 8 post-passaging (p16), for CD9, TRA-1-60, SSEA-3, OCT-4, GPR64, CDCP1, F11R, DSG2, CDH3, NLGN4X, and PCDH1. Each column represents the mean ± SEM of 10 individual lines. FSA0006 and TOB0474 were analyzed twice for all markers aside from OCT-4, which was analyzed once. The abnormal lines TOB0218 (StemFlex), MBE2899 (TeSR-E8), and MBE2901 (TeSR-E8) were not included in this analysis. Two-way ANOVA followed by Sidak's multiple comparisons test indicates no statistical difference in each pluripotency marker expression between the two culture conditions.